MedTrace Logo

D2 Versus D1 Gastrectomy of Operable Gastric Cancer

NCT04429841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2020-06-12

No results posted yet for this study

Summary

Surgery is the mainstay treatment of operable gastric carcinoma but the optimal extent of lymph node (LN) dissection is controversial. The aim of this observational study is to assess the outcomes after curative D2 compared to D1 gastrectomy of operable gastric carcinoma regarding operative and long term oncological outcomes.

Conditions

Interventions

PROCEDURE

Radical gastrectomy with D1 lymphadenectomy

PROCEDURE

Radical gastrectomy with D2 lymphadenectomy

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed Elmessiry, MD · Assistant Professor of Surgery

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-01-31
Completion
2020-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429841 on ClinicalTrials.gov